Skip to main content

Table 1 Clinical characteristics of patients

From: Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

  Control Rheumatoid arthritis Ankylosing spondylitis
Number of patients 30 24 15
Mean age, years (range) 63 (30–83) 56 (26–77) 41 (26–57)
Number of women (%) 23 (76.7) 16 (66.7) 4 (26.7)
Disease duration, years (range) 7.4 (1–22) 12 (3–32) 17 (6–30)
Infliximab treatment (mg/kg) 0 3 5
Concomitant medication    
   Number of patients with    
NSAID 22 10 5
Corticosteroids 19 19 8
Methotrexate 30 24 6
Side effects    
   Number of patients with    
Allergy   3 Ma, 1 Sa 1 Sa
Infections   2 Ma, 2 Sa 2 Ma, 1 Sa
Other (amyloidosis)   0 3 Ma
Inefficacy of treatment    
   Number of patients   2 2
   Months 8 and 10 Months 5 and 7
  1. AS, ankylosing spondylitis; NSAID, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis.
  2. aSignificant side effects and inefficacy that could lead to infliximab discontinuation. If side effects were severe (S), infliximab was stopped; thus nine patients discontinued infliximab treatment before the end of the study, between 3 and 18 months in 5 RA and 2 AS patients. If moderate (M), infliximab was continued. The severe infections were pulmonary tuberculosis (RA), septic pericarditis (AS) and Streptococcus bovis endocarditis (RA). Two severe anaphylactic reactions during infliximab infusion (1 RA, 1 AS) led to discontinuation of treatment and in one case (RA) required resuscitation. Three patients with severe long-standing AS were suspected of amyloidosis at the start of infliximab treatment because of nephritic proteinuria. The diagnosis was confirmed by renal biopsy and the infusion carried out.